252 related articles for article (PubMed ID: 28942113)
1. Novel SERMs based on 3-aryl-4-aryloxy-2H-chromen-2-one skeleton - A possible way to dual ERα/VEGFR-2 ligands for treatment of breast cancer.
Luo G; Li X; Zhang G; Wu C; Tang Z; Liu L; You Q; Xiang H
Eur J Med Chem; 2017 Nov; 140():252-273. PubMed ID: 28942113
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, biological evaluation and molecular docking studies of novel 3-aryl-4-anilino-2H-chromen-2-one derivatives targeting ERα as anti-breast cancer agents.
Luo G; Chen M; Lyu W; Zhao R; Xu Q; You Q; Xiang H
Bioorg Med Chem Lett; 2017 Jun; 27(12):2668-2673. PubMed ID: 28460819
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity relationships of 2, 4-disubstituted pyrimidines as dual ERα/VEGFR-2 ligands with anti-breast cancer activity.
Luo G; Tang Z; Lao K; Li X; You Q; Xiang H
Eur J Med Chem; 2018 Apr; 150():783-795. PubMed ID: 29587221
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and evaluation of 6-aryl-indenoisoquinolone derivatives dual targeting ERα and VEGFR-2 as anti-breast cancer agents.
Tang Z; Wu C; Wang T; Lao K; Wang Y; Liu L; Muyaba M; Xu P; He C; Luo G; Qian Z; Niu S; Wang L; Wang Y; Xiao H; You Q; Xiang H
Eur J Med Chem; 2016 Aug; 118():328-39. PubMed ID: 27176944
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of 3-aryl-quinolin derivatives as anti-breast cancer agents targeting ERα and VEGFR-2.
Li X; Wu C; Lin X; Cai X; Liu L; Luo G; You Q; Xiang H
Eur J Med Chem; 2019 Jan; 161():445-455. PubMed ID: 30384047
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel 2H-chromene-3-carbonyl derivatives as selective estrogen receptor degraders (SERDs): Design, synthesis and biological evaluation.
Lu X; Teng Y; Lin X; Xiao M; Liu C; Chi X; Zhang Y; Luo G; Xiang H
Bioorg Chem; 2021 Apr; 109():104714. PubMed ID: 33618254
[TBL] [Abstract][Full Text] [Related]
7. Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft.
Saxena R; Fatima I; Chandra V; Blesson CS; Kharkwal G; Hussain MK; Hajela K; Roy BG; Dwivedi A
Steroids; 2013 Nov; 78(11):1071-86. PubMed ID: 23891847
[TBL] [Abstract][Full Text] [Related]
8. Selective estrogen receptor modulators with conformationally restricted side chains. Synthesis and structure-activity relationship of ERalpha-selective tetrahydroisoquinoline ligands.
Renaud J; Bischoff SF; Buhl T; Floersheim P; Fournier B; Geiser M; Halleux C; Kallen J; Keller H; Ramage P
J Med Chem; 2005 Jan; 48(2):364-79. PubMed ID: 15658851
[TBL] [Abstract][Full Text] [Related]
9. A novel dual-target steroid sulfatase inhibitor and antiestrogen: SR 16157, a promising agent for the therapy of breast cancer.
Rasmussen LM; Zaveri NT; Stenvang J; Peters RH; Lykkesfeldt AE
Breast Cancer Res Treat; 2007 Dec; 106(2):191-203. PubMed ID: 17268816
[TBL] [Abstract][Full Text] [Related]
10. New Coumarin Derivatives as Anti-Breast and Anti-Cervical Cancer Agents Targeting VEGFR-2 and p38α MAPK.
Batran RZ; Dawood DH; El-Seginy SA; Ali MM; Maher TJ; Gugnani KS; Rondon-Ortiz AN
Arch Pharm (Weinheim); 2017 Sep; 350(9):. PubMed ID: 28787092
[TBL] [Abstract][Full Text] [Related]
11. Manipulating Estrogenic/Anti-Estrogenic Activity of Triphenylethylenes towards Development of Novel Anti-Neoplastic SERMs.
Elnakib HE; Ramsis MM; Albably NO; Vector MA; Weigand JJ; Schwedtmann K; Wober J; Zierau O; Vollmer G; Abadi AH; Ahmed NS
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830456
[TBL] [Abstract][Full Text] [Related]
12. Impact of ER520, a candidate of selective estrogen receptor modulators, on in vitro cell growth, migration, invasion, angiogenesis and in vivo tumor xenograft of human breast cancer cells.
Wang L; Wang Y; Du H; Jiang Y; Tang Z; Liu H; Xiang H; Xiao H
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1247-57. PubMed ID: 26464351
[TBL] [Abstract][Full Text] [Related]
13. Development of the β-lactam type molecular scaffold for selective estrogen receptor α modulator action: synthesis and cytotoxic effects in MCF-7 breast cancer cells.
Carr M; Knox AJ; Lloyd DG; Zisterer DM; Meegan MJ
J Enzyme Inhib Med Chem; 2016; 31(sup3):117-130. PubMed ID: 27476825
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, structure-activity relationships and antagonistic effects in human MCF-7 breast cancer cells of flexible estrogen receptor modulators.
Lloyd DG; Smith HM; O'Sullivan T; Zisterer DM; Meegan MJ
Med Chem; 2005 Jul; 1(4):335-53. PubMed ID: 16789891
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors.
Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI
Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536
[TBL] [Abstract][Full Text] [Related]
16. The selective estrogen receptor modulator bazedoxifene inhibits hormone-independent breast cancer cell growth and down-regulates estrogen receptor α and cyclin D1.
Lewis-Wambi JS; Kim H; Curpan R; Grigg R; Sarker MA; Jordan VC
Mol Pharmacol; 2011 Oct; 80(4):610-20. PubMed ID: 21737572
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of novel dual-acting modulators targeting both estrogen receptor α (ERα) and lysine-specific demethylase 1 (LSD1) for treatment of breast cancer.
He M; Ning W; Hu Z; Huang J; Dong C; Zhou HB
Eur J Med Chem; 2020 Jun; 195():112281. PubMed ID: 32283297
[TBL] [Abstract][Full Text] [Related]
18. Acteoside and martynoside exhibit estrogenic/antiestrogenic properties.
Papoutsi Z; Kassi E; Mitakou S; Aligiannis N; Tsiapara A; Chrousos GP; Moutsatsou P
J Steroid Biochem Mol Biol; 2006 Jan; 98(1):63-71. PubMed ID: 16198557
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of angiogenesis by selective estrogen receptor modulators through blockade of cholesterol trafficking rather than estrogen receptor antagonism.
Shim JS; Li RJ; Lv J; Head SA; Yang EJ; Liu JO
Cancer Lett; 2015 Jun; 362(1):106-15. PubMed ID: 25799952
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of 2,3-diaryl isoquinolinone derivatives as anti-breast cancer agents targeting ERα and VEGFR-2.
Tang Z; Niu S; Liu F; Lao K; Miao J; Ji J; Wang X; Yan M; Zhang L; You Q; Xiao H; Xiang H
Bioorg Med Chem Lett; 2014 May; 24(9):2129-33. PubMed ID: 24721727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
